The beneficiary effects of IVIg on MG patients and the inverse relationship between circulating Tregs/CTLA-4+ Tregs and disease severity of MG patients prompted us to investigate the mechanisms of expansion of Tregs/CTLA-4+ Tregs by IVIg. Here, CTLA4 is linked to myasthenia gravis.